|
Integrated Assessment of Immune-Inflammatory and Metabolic Biomarkers for Prediction of Coronary No-Reflow Following Primary PCI in STEMI Patients
RECRUITINGSponsored by Sohag University
Actively Recruiting
SponsorSohag University
Started2026-09-01
Est. completion2027-05-01
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT07890168
Summary
This study aims to evaluate the combined predictive value of immune-inflammatory and metabolic biomarkers for coronary no-reflow following primary percutaneous coronary intervention (PCI) in patients with ST-segment elevation myocardial infarction (STEMI), with the goal of improving early risk stratification and clinical decision-making.
Eligibility
Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria: * Age ≥18 years old. * Both sexes. * Diagnosis of ST-segment elevation myocardial infarction (STEMI) according to current ESC/ACC guidelines. * Presentation within 12 hours of symptom onset. * Undergoing primary percutaneous coronary intervention (PCI) as the reperfusion strategy. Exclusion Criteria: * Active infection or sepsis. * Chronic inflammatory or autoimmune diseases. * Hematological disorders. * Active malignancy. * Severe liver disease. * End-stage renal disease requires dialysis. * Previous coronary artery bypass graft surgery (CABG). * Current use of chronic corticosteroid or immunosuppressive therapy.
Conditions7
Coronary No-ReflowHeart DiseaseImmune-InflammatoryIntegrated AssessmentMetabolic BiomarkersPrimary Percutaneous Coronary InterventionST Segment Elevation Myocardial Infarction
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
SponsorSohag University
Started2026-09-01
Est. completion2027-05-01
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT07890168